more

MannKind (MNKD)

(Delayed Data from NSDQ)

$5.82 USD

-0.07 (-1.19%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 04,2020

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

MNKDNegative Net Change

Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research Published on October 28,2020

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNKDNegative Net Change

MannKind (MNKD) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research Published on August 20,2020

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

medical

MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 05,2020

MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

MNKDNegative Net Change

MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research Published on July 29,2020

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNKDNegative Net Change

MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research Published on June 22,2020

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

medical

Implied Volatility Surging for MannKind (MNKD) Stock Options

by Zacks Equity Research Published on June 18,2020

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

MNKDNegative Net Change

medical

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 06,2020

MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MNKDNegative Net Change

MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research Published on April 28,2020

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNKDNegative Net Change

United Therapeutics' Trevyent NDA for PAH Accepted by FDA

by Zacks Equity Research Published on September 12,2019

United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

pharmaceuticals

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

by Zacks Equity Research Published on May 02,2019

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

pharmaceuticals

Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

by Zacks Equity Research Published on November 16,2018

Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

biotechs

United Therapeutics In-Licenses Rights to IPF Candidate

by Zacks Equity Research Published on September 18,2018

United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.

Implied Volatility Surging for MannKind (MNKD) Stock Options

by Zacks Equity Research Published on September 10,2018

MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.

MNKDNegative Net Change

The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

by Zacks Equity Research Published on September 06,2018

The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

MannKind Stock Up on Licensing Deal With United Therapeutics

by Zacks Equity Research Published on September 05,2018

MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

by Zacks Equity Research Published on September 05,2018

Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?

by Zacks Equity Research Published on August 09,2018

Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.

MNKDNegative Net Change

MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 02,2018

MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and -18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?